The convenience of increase in the sample is particularly necessary in the subgroup of patients with FTD/ALS, where the small number of cases does not allow statistical analysis in any molecular marker, such as cytoplasmatic TDP-43. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.